|
コンドウ ツネノリ
Kondou Tsunenori
近藤 恒徳 所属 医学部 医学科（附属足立医療センター） 職種 教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. |
| 掲載誌名 | 正式名：International journal of clinical oncology 略 称：Int J Clin Oncol ISSNコード：14377772/13419625 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 25(4),pp.705-712 |
| 著者・共著者 | ISHIHARA Hiroki†*, TAKAGI Toshio, KONDO Tsunenori, FUKUDA Hironori, TACHIBANA Hidekazu, YOSHIDA Kazuhiko, IIZUKA Junpei, KOBAYASHI Hirohito, OKUMI Masayoshi, ISHIDA Hideki, TANABE Kazunari |
| 発行年月 | 2020/04 |
| 概要 | BACKGROUND:The aim of this study was to compare the efficacy and safety of nivolumab as second-line and later-line (third-line or thereafter) therapy in metastatic renal cell carcinoma (mRCC).METHODS:Sixty-seven patients who received nivolumab after the failure of at least one molecular-targeted therapy were evaluated. The patients were divided into two groups based on the line of nivolumab: second-line and later-line groups. Efficacy was assessed using progression-free survival and overall survival (OS) after nivolumab initiation, and objective response rate. Safety was assessed using the incidence of immune-related adverse events. These outcomes were compared between the second-line and later-line groups.RESULTS:Forty-two patients (62.7%) received nivolumab as second-line therapy. There was no significant difference in the progression-free survival (median: 5.06 vs. 6.28 months, p = 0.691) or objective response rate (35.7% vs. 32.0%, p = 0.757) between the second-line and later-line groups. The OS tended to be longer in the second-line group (not reached vs. 26.0 months, p = 0.118), and the rate of patients who received subsequent therapy after nivolumab failure was significantly higher in the second-line group (90.9% vs. 55.0%, p = 0.0025). There was no difference in the incidences of immune-related adverse events between the second-line and later-line groups (any grade: 54.8% vs. 48.0%, p = 0.592; grade ≥ 3: 19.1% vs. 20.0%, p = 0.924).CONCLUSIONS:The efficacy of nivolumab did not deteriorate and the tolerability was also maintained even in later-line therapy. However, a tendency of longer OS and a higher chance of subsequent therapy after nivolumab failure were observed with nivolumab as second-line therapy. |
| DOI | 10.1007/s10147-019-01605-9 |
| PMID | 31858306 |